Chen AY - Search Results

1

p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.

Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS. Vollmer CM, et al. Among authors: chen ay. Cancer Res. 1999 Sep 1;59(17):4369-74. Cancer Res. 1999. PMID: 10485485

2

Transduction of murine and human tumors using recombinant adenovirus vectors.

Toloza EM, Hunt K, Miller AR, McBride W, Lau R, Swisher S, Rhoades K, Arthur J, Choi J, Chen L, Chang P, Chen A, Glaspy J, Economou JS. Toloza EM, et al. Ann Surg Oncol. 1997 Jan;4(1):70-9. doi: 10.1007/BF02316813. Ann Surg Oncol. 1997. PMID: 8985520

3

Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.

Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS. Ribas A, et al. Among authors: chen ay. Cancer Res. 1997 Jul 15;57(14):2865-9. Cancer Res. 1997. PMID: 9230191

4

Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.

Ribas A, Butterfield LH, McBride WH, Dissette VB, Koh A, Vollmer CM, Hu B, Chen AY, Glaspy JA, Economou JS. Ribas A, et al. Among authors: chen ay. Cancer Gene Ther. 1999 Nov-Dec;6(6):523-36. doi: 10.1038/sj.cgt.7700076. Cancer Gene Ther. 1999. PMID: 10608349

5

Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.

Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS. Ribas A, et al. Among authors: chen ay. J Immunother. 2000 Jan;23(1):59-66. doi: 10.1097/00002371-200001000-00008. J Immunother. 2000. PMID: 10687138

6

The potential role of radiation therapy to the primary site of disease in stage IV breast cancer presenting with synchronous metastasis.

Mayadev J, Daly M, Chen A, Bold R, Chew H. Mayadev J, et al. Clin Breast Cancer. 2014 Feb;14(1):10-2. doi: 10.1016/j.clbc.2013.08.010. Epub 2013 Oct 30. Clin Breast Cancer. 2014. PMID: 24183416 No abstract available.

7

Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2.

Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J. Tsutani Y, et al. Clin Lung Cancer. 2023 Jun;24(4):376-380. doi: 10.1016/j.cllc.2023.02.002. Epub 2023 Feb 8. Clin Lung Cancer. 2023. PMID: 36872181 Free article.

8

Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations.

Harris JP, Fujimoto DK, Nagasaka M, Ku E, Harada G, Keshava H, Mahtabifard A, Longoria J, Patel N, Seyedin S, Simon A, Chen A. Harris JP, et al. Clin Lung Cancer. 2022 Jun;23(4):333-344. doi: 10.1016/j.cllc.2022.02.001. Epub 2022 Feb 10. Clin Lung Cancer. 2022. PMID: 35256282 Free article.

9

Adjuvant external beam radiation for medullary thyroid carcinoma.

Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD. Martinez SR, et al. J Surg Oncol. 2010 Aug 1;102(2):175-8. doi: 10.1002/jso.21557. J Surg Oncol. 2010. PMID: 20648590 Free PMC article.

10

Utilization and impact of a postmastectomy radiation boost for invasive breast cancer.

Mayadev J, Fish K, Valicenti R, West D, Chen A, Martinez S, Phillips T. Mayadev J, et al. Pract Radiat Oncol. 2014 Nov-Dec;4(6):e269-78. doi: 10.1016/j.prro.2014.05.006. Epub 2014 Jul 11. Pract Radiat Oncol. 2014. PMID: 25407878

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

687 results

Search Page

Filters